Currently set to Index
Currently set to Follow
PROFILE
search
ask age2b
CART

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

By AGE2B team
November 4, 2021
0
0

Christopher P Cannon 1, Richard Pratley 1, Samuel Dagogo-Jack 1, James Mancuso 1, Susan Huyck 1, Urszula Masiukiewicz 1, Bernard Charbonnel 1, Robert Frederich 1, Silvina Gallo 1, Francesco Cosentino 1, Weichung J Shih 1, Ira Gantz 1, Steven G Terra 1, David Z I Cherney 1, Darren K McGuire 1, VERTIS CV Investigators

Main idea: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events.

Abstract: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established.

Methods: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease. The primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome. The first key secondary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure.

Results: A total of 8246 patients underwent randomization and were followed for a mean of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients. Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5499 patients.

Source NIH

Leave a Reply

Ask your question

We read all your emails and your text. Your question will be responded by our specialists, or one of the doctors we're working with, or our community

Please complete the required fields.